A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and ...

Amgen Inc. ( NASDAQ: AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & ...

A new trial has found that a weight loss drug taken monthly helps people lose 20 percent of their body weight. Weight loss medications such as Ozempic, Wegovy and Mounjaro have become popular and now ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

The S&P 500 advanced 1% on Monday, June 23, 2025, as investors weighed the potential severity and impact of Iran's ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with ...

Amgen (NASDAQ:AMGN) announced on Monday that its new weight loss treatment, MariTide, resulted in an average weight loss of ...

Amgen is expanding development plans for its weight-loss drug MariTide to study its use for heart disease and sleep apnea.